The battle of wills between Roche and NICE over the breast cancer drug Kadcyla has entered a new phase – and one that could have an impact for the whole UK industry. Yesterday saw Roche mount ...

The combination of two HER2-targeting drugs – Seagen's oral Tukysa and Roche's intravenous antibody-drug conjugate (ADC) Kadcyla – has shown a benefit over Kadcyla alone as a second-line ...

It launched Ujvira, (Trastuzumab Emtansine biosimilar) in India, which is the first biosimilar of an Antibody Drug Conjugate (ADC) Kadcyla and a highly effective drug for treatingboth early and ...

Welcome to our quarterly update relating to biologics and biosimilars, including post-grant and patent litigation challenges to blockbuster biologics. Since the enactment of the Biologics Price ...

6367.T Daikin Industries,Ltd.